New Drugs Update: Three Novel Treatments for SARS-CoV-2

Coronavirus disease 2019 (COVID-19) cases were first reported in China in December 2019. As of June 4, 2022, more than 530 million cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been reported globally, including more than 6.2 million deaths.¹ People of all ages are at risk for SARS-CoV-2 infection and severe illness; however, the probability of serious COVID-19 disease is higher in people 60 years of age or older, those living in a nursing facility or long-term care facility, and people with chronic medical conditions. Mortality is highest in patients older than 70 years of age, regardless of the presence of chronic medical conditions.² In the last two years, in addition to emergence of COVID-19 testing and vaccines, several antiviral treatments and monoclonal antibodies (mAbs) became available and can be used to reduce their chances of being hospitalized or dying from the disease.